Trial Profile
Post-Marketing Surveillance of Safety and Efficacy of Kaletra Tablet in Korean Patients Under the "New Drug Re-Examination"
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Lopinavir/ritonavir (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Abbott Laboratories; AbbVie
- 17 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Sep 2014 Planned End Date changed from 1 Aug 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov.
- 09 Sep 2014 Planned primary completion date changed from 1 Jan 2015 to 1 Nov 2014 as reported by ClinicalTrials.gov.